JP2017514834A - Ｈｃｖ感染症を治療するための組合せ療法 - Google Patents

Ｈｃｖ感染症を治療するための組合せ療法 Download PDF

Info

Publication number
JP2017514834A
JP2017514834A JP2016565327A JP2016565327A JP2017514834A JP 2017514834 A JP2017514834 A JP 2017514834A JP 2016565327 A JP2016565327 A JP 2016565327A JP 2016565327 A JP2016565327 A JP 2016565327A JP 2017514834 A JP2017514834 A JP 2017514834A
Authority
JP
Japan
Prior art keywords
day
hcv
sofosbuvir
faludaprevir
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016565327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514834A5 (enExample
Inventor
ネザム エイチ アフダル
ネザム エイチ アフダル
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2017514834A publication Critical patent/JP2017514834A/ja
Publication of JP2017514834A5 publication Critical patent/JP2017514834A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016565327A 2014-05-02 2015-04-30 Ｈｃｖ感染症を治療するための組合せ療法 Pending JP2017514834A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987682P 2014-05-02 2014-05-02
US61/987,682 2014-05-02
PCT/EP2015/059557 WO2015166071A1 (en) 2014-05-02 2015-04-30 Combination therapy for treating hcv infection

Publications (2)

Publication Number Publication Date
JP2017514834A true JP2017514834A (ja) 2017-06-08
JP2017514834A5 JP2017514834A5 (enExample) 2018-06-14

Family

ID=53052853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565327A Pending JP2017514834A (ja) 2014-05-02 2015-04-30 Ｈｃｖ感染症を治療するための組合せ療法

Country Status (4)

Country Link
US (1) US20170049797A1 (enExample)
EP (1) EP3137075A1 (enExample)
JP (1) JP2017514834A (enExample)
WO (1) WO2015166071A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2015443A3 (cs) * 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANITA KOHLI; ZAYANI SIMS; MIRIAM MARTI; AMY NELSON; ET AL: "COMBINATION ORAL, HEPATITIS C ANTIVIRAL THERAPY FOR 6 OR 12 WEEKS: RESULTS OF THE SYNERGY TRIAL", 21ST CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS, JPN5017003393, April 2014 (2014-04-01), pages 1 - 8, ISSN: 0004136052 *
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014/4, VOL.58(4), P.2369-2376, JPN6019007736, ISSN: 0004136053 *
移植, 2012, VOL.47(6), P.372-378, JPN6019007737, ISSN: 0004136054 *
肝胆膵, 2013, VOL.67(6), P.886-892, JPN6019007739, ISSN: 0004136055 *

Also Published As

Publication number Publication date
WO2015166071A1 (en) 2015-11-05
EP3137075A1 (en) 2017-03-08
US20170049797A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
JP5539363B2 (ja) インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
US20110171174A1 (en) Synergistic Combinations of a Macrocyclic Inhibitor of HCV and a Nucleoside
JP2012519181A5 (enExample)
WO2010031832A2 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
KR20120106942A (ko) Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
JP2016153402A (ja) Ｃ型肝炎ウイルス感染症の新規治療
US20170224765A1 (en) Treatments of hepatitis c virus infection
JP2017514834A (ja) Ｈｃｖ感染症を治療するための組合せ療法
JP5989635B2 (ja) Ｈｃｖの大環状阻害剤、非ヌクレオシドおよびヌクレオシドの組合せ
MX2015002684A (es) Combinacion de un inhibidor macrociclico de proteasas del vhc, un inhibidor del vhc no nucleosidico y ritonavir.
JP2014509628A (ja) Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
US20150328280A1 (en) Alisporivr for treatment of hepatitis c virus infection
US20150104415A1 (en) Treatments of Hepatitis C virus infection
TH1901004574A (th) เกลือ นิวคลีโอไทด์ เฮมิ-ซัลเฟต สำหรับการรักษาไวรัสตับอักเสบซี
HK1161833A (en) Synergistic combinations of a macrocyclic inhibitor of hcv and nucleoside
TW201536297A (zh) Ｃ型肝炎病毒感染之新治療方法
NZ615539B2 (en) Treatment of hepatitis c virus infection with alisporivir

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190307

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191024